# US 2010/0168212 A1 · Oligomers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168212 A1
- Document ID: US20100168212A1
- Status: Published application
- Kind: A1
- Application number: 12/556,626
- Filed: 2009-09-10
- Published: 2010-07-01
- Earliest claimed: 2008-09-11
- Assignees: Royal Holloway, University of London
- Inventors: Linda POPPLEWELL; Ian Graham; John George Dickson
- Web page: https://patentgrep.com/patent/US20100168212A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 2310/11: Antisense
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/351: Conjugate
- C12N 2310/3513: Protein; Peptide
- C12N 2320/31: Combination therapy
- C12N 2320/35: based on a specific dosage / administration regimen
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.

## Claims

### Claim 1

An oligomer for ameliorating DMD, the oligomer comprising at least 25 contiguous bases of a base sequence selected from the group consisting of:
(SEQ ID NO: 1)
a)
XGA AAA CGC CGC CAX XXC XCA ACA GAX CXG;
(SEQ ID NO: 2)
b)
CAX AAX GAA AAC GCC GCC AXX XCX CAA CAG;
(SEQ ID NO: 3)
c)
XGX XCA GCX XCX GXX AGC CAC XGA XXA AAX;
(SEQ ID NO: 4)
d)
CAG XXX GCC GCX GCC CAA XGC CAX CCX GGA;
(SEQ ID NO: 5)
e)
XXG CCG CXG CCC AAX GCC AXC CXG GAG XXC;
(SEQ ID NO: 6)
f)
XGC XGC XCX XXX CCA GGX XCA AGX GGG AXA;
(SEQ ID NO: 7)
g)
CXX XXA GXX GCX GCX CXX XXC CAG GXX CAA;
(SEQ ID NO: 8)
h)
CXX XXC XXX XAG XXG CXG CXC XXX XCC AGG;
(SEQ ID NO: 9)
i)
XXA GXX GCX GCX CXX XXC CAG GXX CAA GXG;
(SEQ ID NO: 10)
j)
CXG XXG CCX CCG GXX CXG AAG GXG XXC XXG;
(SEQ ID NO: 11)
k)
CAA CXG XXG CCX CCG GXX CXG AAG GXG XXC;
and
(SEQ ID NO: 12)
l)
XXG CCX CCG GXX CXG AAG GXG XXC XXG XAC,
wherein X=U or T, wherein the oligomer's base sequence can vary from the above sequence at up to two base positions, and wherein the molecule can bind to a target site to cause exon skipping in an exon of the dystrophin gene.

### Claim 2 (depends on 1)

The oligomer according to claim 1, wherein the exon of the dystrophin gene at which exon skipping is caused is selected from the group consisting of exon 44, 45, 46, and 53.

### Claim 3 (depends on 1)

The oligomer according to claim 1, wherein the oligomer causes an exon skipping rate of at least 50%.

### Claim 4 (depends on 1)

The oligomer according to claim 1, wherein the oligomer is between 25 and 35 bases in length.

### Claim 5 (depends on 1)

The oligomer according to claim 1, wherein the oligomer is 30 bases in length.

### Claim 6 (depends on 1)

The oligomer according to claim 1, wherein the oligomer is conjugated to or complexed with a distinct chemical entity.

### Claim 7 (depends on 1)

The oligomer according to claim 1, wherein the oligomer is a phosphorodiamidate morpholino oligonucleotide (PMO).

### Claim 8 (depends on 1)

A vector for ameliorating DMD, the vector encoding an oligomer according to claim 1, wherein when introduced into a human cell the oligomer is expressed.

### Claim 9 (depends on 1, 8)

A pharmaceutical composition for ameliorating DMD, the composition comprising an oligomer according to claim 1 or a vector according to claim 8, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

### Claim 10 (depends on 9)

A pharmaceutical composition according to claim 9 comprising a plurality of oligomers or vectors encoding oligomers, or a combination of the oligomers and vectors, wherein the oligomers and/or vectors in the pharmaceutical composition cause skipping in a plurality of exons.

### Claim 11 (depends on 1, 8)

A method of ameliorating DMD in a human patient, the method comprising: administering a therapeutically effective amount of an oligomer according to claim 1 or a vector according to claim 8 to the patient such that the DMD is ameliorated.

### Claim 12 (depends on 11)

The method according to claim 11 comprising administering a therapeutically effective amount of a plurality of oligomers to the patient, wherein the oligomers cause skipping in a plurality of exons.
